Lunden Neither covid-19 Pfizer / BioNTech vaccine produced an adequate immune response to protect against the currently prevalent coronavirus mutations. A British study published in Science and Reuters showed that one of the people who have contracted Covid-19 disease is one of the most common people.
A study by the University of London in London examined the immune response of healthcare professionals in Britain after the first two Pfizer / BioNTech vaccinations. Researchers found that people who contracted the disease without symptoms or with a moderate course had a single mRNA vaccine and strong protection against coronavirus mutations in Britain and South Africa. Those who did not report the disease showed a stronger immune response, posing a potential risk of developing infection.
Our findings show that people who were vaccinated in the first two and who did not become infected with SARS-CoV-2 were not fully protected from the alleged births and mutations. Rosemary Poitunov, professor of immunology at Krlovsk University in London, said the study highlights the importance of second-line vaccines to protect the population.
The study tested blood samples for the presence and level of immunity against the original SARS-CoV-2 strain and the mutations that first appeared in Britain (B 1.1.7) and South Africa (B 1,351). The researchers found that production of T cells, B cells, and antibodies is associated with disease delay. He studied only two mutations, but assumed their findings would be valid for the Brazilian and Indian mutations.
“Reader. Infuriatingly humble travel enthusiast. Extreme food scholar. Writer. Communicator.”